AR and non-small cell lung carcinoma: Although the underlying mechanisms driving neuroendocrine differentiation in anti-EGFR-treated NSCLC and anti-hormone therapy-treated PC remains unclear, switches between different cell fates or acquisition of specific oncogenic mutations occur in response to AR blockade/during the evolution to NEPC.